EIF2AK3 and hepatocellular carcinoma: HCC patients with pERK+/pAkt− CTCs were most sensitive to sorafenib. The proportion of pERK+/pAkt− CTCs was significantly correlated with shorter PFS, and could be an independent predictive factor in HCC patients treated with sorafenib. Li et al., 2016 (48)